Illumina, Inc. (NASDAQ:ILMN) Stock Position Decreased by Natixis Advisors LLC

Natixis Advisors LLC cut its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 371,611 shares of the life sciences company’s stock after selling 1,368 shares during the period. Natixis Advisors LLC’s holdings in Illumina were worth $48,461,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Primecap Management Co. CA raised its holdings in Illumina by 462.5% during the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock worth $253,514,000 after buying an additional 1,997,010 shares during the period. Millennium Management LLC increased its position in shares of Illumina by 305.0% in the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock worth $155,067,000 after acquiring an additional 1,118,747 shares in the last quarter. Capital World Investors raised its holdings in shares of Illumina by 41.1% during the first quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock valued at $378,111,000 after acquiring an additional 801,814 shares during the period. Marshall Wace LLP purchased a new stake in shares of Illumina in the 2nd quarter valued at approximately $77,628,000. Finally, Swedbank AB acquired a new position in Illumina in the 1st quarter worth approximately $99,682,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $135.05 on Monday. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The business’s fifty day moving average price is $139.66 and its two-hundred day moving average price is $124.31. Illumina, Inc. has a fifty-two week low of $92.69 and a fifty-two week high of $156.66. The stock has a market capitalization of $21.42 billion, a price-to-earnings ratio of -13.56 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same quarter in the prior year, the firm earned $0.33 EPS. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. As a group, analysts predict that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Daiwa Capital Markets upgraded Illumina from a “neutral” rating to a “buy” rating and increased their target price for the company from $120.00 to $154.00 in a report on Friday, August 16th. Scotiabank decreased their price objective on Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research report on Thursday, August 15th. Citigroup upped their target price on Illumina from $155.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a report on Thursday, October 17th. Finally, Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective for the company in a research report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $164.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.